CoChat

Paradox of glycemic management: multimorbidity, glycemic control, and high-risk medication use among adults with diabetes

Open access
McCoy, Rozalina G, Lipska, Kasia J, Van Houten, Holly K, Shah, Nilay D · 2020 · BMJ Open Diabetes Research & Care

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Abstract

Introduction: Glycemic targets and glucose-lowering regimens should be individualized based on multiple factors, including the presence of comorbidities. We examined contemporary patterns of glycemic control and use of medications known to cause hypoglycemia among adults with diabetes across age and multimorbidity. Research design and methods: We retrospectively examined glycosylated hemoglobin (HbA 1c) levels and rates of insulin/sulfonylurea use as a function of age and multimorbidity using administrative claims and laboratory data for adults with type 2 diabetes included in OptumLabs Data Warehouse, 1 January 2014 to 31 December 2016. Comorbidity burden was assessed by counts of any of 16 comorbidities specified by guidelines as warranting relaxation of HbA 1c targets, classified as being diabetes concordant (diabetes complications or risk factors), discordant (unrelated to diabetes), or advanced (life limiting). Results: Among 194 157 patients with type 2 diabetes included in the study, 45.2% had only concordant comorbidities, 30.6% concordant and discordant, 2.7% only discordant, and 13.0% had ≥1 advanced comorbidity. Mean HbA 1c was 7.7% among 18–44 year-olds versus 6.9% among ≥75 year-olds, and was higher among patients with comorbidities: 7.3% with concordant only, 7.1% with discordant only, 7.1% with concordant and discordant, and 7.0% with advanced comorbidities compared with 7.4% among patients without comorbidities. The odds of insulin use decreased with age (OR 0.51 (95% CI 0.48 to 0.54) for age ≥75 vs 18–44 years) but increased with accumulation of concordant (OR 5.50 (95% CI 5.22 to 5.79) for ≥3 vs none), discordant (OR 1.72 (95% CI 1.60 to 1.86) for ≥3 vs none), and advanced (OR 1.45 (95% CI 1.25 to 1.68) for ≥2 vs none) comorbidities. Conversely, sulfonylurea use increased with age (OR 1.36 (95% CI 1.29 to 1.44) for age ≥75 vs 18–44 years) but decreased with accumulation of concordant (OR 0.76 (95% CI 0.73 to 0.79) for ≥3 vs none), discordant (OR 0.70 (95% CI 0.64 to 0.76) for ≥3 vs none), but not advanced (OR 0.86 (95% CI 0.74 to 1.01) for ≥2 vs none) comorbidities. Conclusions: The proportion of patients achieving low HbA 1c levels was highest among older and multimorbid patients. Older patients and patients with higher comorbidity burden were more likely to be treated with insulin to achieve these HbA 1c levels despite potential for hypoglycemia and uncertain long-term benefit.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/bmjdrc-2019-001007

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Glycemic control and sulfonylurea use in the context of advanced age and multimorbidity. Shown are the proportions of patients within each hemoglobin A1c (HbA1c) category treated with sulfonylurea (no insulin) as a function of (A) age, (B) Charlson index, (C) number of concordant comorbidities among patients with only concordant comorbidities, (D) number of discordant comorbidities among patients with only discordant comorbidities, (E) number of concordant and/or discordant comorbidities among patients with both, and (F) total number of comorbidities among patients with at least one advanced illness, with or without concurrent concordant and/or discordant conditions.
Figure 1 Glycemic control and sulfonylurea use in the context of advanced age and multimorbidity. Shown are the proportions of patients within each hemoglobin A1c (HbA1c) category treated with sulfonylurea (no insulin) as a function of (A) age, (B) Charlson index, (C) number of concordant comorbidities among patients with only concordant comorbidities, (D) number of discordant comorbidities among patients with only discordant comorbidities, (E) number of concordant and/or discordant comorbidities among patients with both, and (F) total number of comorbidities among patients with at least one advanced illness, with or without concurrent concordant and/or discordant conditions.CC BY-NC · PubMed Central
Figure 2 Glycemic control and insulin use in the context of advanced age and multimorbidity. Shown are the proportions of patients within each hemoglobin A1c (HbA1c) category treated with insulin (with or without sulfonylurea) as a function of (A) age, (B) Charlson index, (C) number of concordant comorbidities among patients with only concordant comorbidities, (D) number of discordant comorbidities among patients with only discordant comorbidities, (E) number of concordant and/or discordant comorbidities among patients with both, and (F) total number of comorbidities among patients with at least one advanced illness, with or without concurrent concordant and/or discordant conditions.
Figure 2 Glycemic control and insulin use in the context of advanced age and multimorbidity. Shown are the proportions of patients within each hemoglobin A1c (HbA1c) category treated with insulin (with or without sulfonylurea) as a function of (A) age, (B) Charlson index, (C) number of concordant comorbidities among patients with only concordant comorbidities, (D) number of discordant comorbidities among patients with only discordant comorbidities, (E) number of concordant and/or discordant comorbidities among patients with both, and (F) total number of comorbidities among patients with at least one advanced illness, with or without concurrent concordant and/or discordant conditions.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 36 references

Research works printed but not linked: 1

  1. OptumLabs . OptumLabs and OptumLabs data Warehouse (OLDW) descriptions and citation. Cambridge, MA, 2019 PDF. Reproduced with permission from OptumLabs.

Cited by

See all 51

Metadata

Authors
McCoy, R. G., Lipska, K. J., Van Houten, H. K., & Shah, N. D.
Affiliations
  • Mayo Clinic (US)
  • Yale University (US)
  • Division of Health Care Policy & Research, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
Corresponding author
McCoy, Rozalina G
Venue
BMJ Open Diabetes Research & Care
Publisher
BMJ
Published
2020-02
Volume
8
Issue
1
Pages
e001007
ISSN
2052-4897 (ISSN-L)
OpenAlex
W3007546177
Cited by
51
References
36
Citations by year
2026: 10 · 2025: 7 · 2024: 6 · 2023: 13 · 2022: 6 · 2021: 8 · 2020: 1
FWCI
5.28
Type
journal article
Language
en
Open access
Locations
  • BMJ Open Diabetes Research & Care (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Institute of Diabetes and Digestive and Kidney Diseases (K23DK114497)
  • Agency for Healthcare Research and Quality (1U19HS024075)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Epidemiology › Chronic Disease Management Strategies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, glycemic control, HbA1c, multimorbidity, insulin use, sulfonylureas, hypoglycemic medications, age differences, individualized glycemic targets, diabetes complications, older adults, medication use patterns
MeSH terms
Multimorbidity, Glycemic Control, Adolescent, Adult, Aged, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Longitudinal Studies, Male, Middle Aged, Retrospective Studies, Risk Factors, Sulfonylurea Compounds, Diabetes Complications, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Paradox of glycemic management: multimorbidity, glycemic control, and high-risk medication use among adults with diabetes. https://app.cochat.ai/papers/10.1136/bmjdrc-2019-001007
The paper
McCoy, R. G., Lipska, K. J., Van Houten, H. K., & Shah, N. D. (2020). Paradox of glycemic management: multimorbidity, glycemic control, and high-risk medication use among adults with diabetes. BMJ Open Diabetes Research & Care. https://doi.org/10.1136/bmjdrc-2019-001007

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.